Covid-19 variant BA.2.86 (Pirola)
Pro Research Analysisby 
Searched over 200M research papers
Emergence and Global Spread of BA.2.86 (Pirola) Variant
The BA.2.86 (Pirola) variant is a new subvariant of SARS-CoV-2 that has attracted significant attention due to its high number of mutations, particularly in the spike protein. First identified in Denmark in July 2023, BA.2.86 has since been detected in several countries, including Israel, the UK, the US, South Africa, and China, with cases appearing to be unlinked, suggesting community transmission in some regions Looi2023Satapathy2024Mohapatra2023+1 MORE. The World Health Organization (WHO) has designated BA.2.86 as a variant under monitoring due to its unique genetic profile and potential public health implications Mohapatra2023Scarpa2023.
Genetic Mutations and Immune Evasion
BA.2.86 is notable for carrying over 30 mutations in its spike protein, some of which are shared with previous variants like BA.2, while others, such as P681R and F486P, are unique or particularly significant. These mutations may enhance the variant’s ability to evade immune responses, including those induced by vaccination or prior infection Satapathy2024Scarpa2023Abdolreza2024. However, not all mutations necessarily increase the virus’s fitness or pathogenicity; some may be neutral, while others could confer a selective advantage .
Infectivity, Transmission, and Pathogenicity
Early research indicates that BA.2.86 has a higher transmission rate compared to earlier variants, contributing to its spread across multiple regions . Laboratory studies show that BA.2.86 exhibits relatively high infectivity and fusogenicity in certain cell types, though its overall ability to bind to human receptors is not significantly greater than previous variants Qu2024Popović2024Qu2023. Importantly, the driving force for antigen-receptor binding in BA.2.86 is similar to or lower than that of other recent variants, suggesting it may not be more aggressive in terms of disease severity .
Immune Response and Vaccine Effectiveness
BA.2.86 demonstrates a heightened ability to evade neutralizing antibodies, but it is less immune evasive than some XBB variants, such as FLip Qu2024Qu2023. Notably, certain monoclonal antibodies, like S309, are ineffective against BA.2.86 due to specific mutations (e.g., D339H) Qu2024Qu2023. Despite these challenges, current data suggest that global immunity—built through vaccination and prior infections—may help modulate the impact of BA.2.86, though ongoing surveillance and updated vaccines remain essential Satapathy2024Abdolreza2024Reinfeld2024+2 MORE.
Clinical Presentation and Public Health Implications
The symptoms associated with BA.2.86 are similar to those of other Omicron subvariants, with a wide range of presentations, including asymptomatic cases. The overall severity of disease appears to be decreasing, but the emergence of new variants like BA.2.86 underscores the need for continued vigilance, updated vaccines, and flexible treatment protocols Abdolreza2024Reinfeld2024. Large public events and international gatherings, such as sporting tournaments, may require additional preventive measures to limit the spread of this and other emerging variants .
Importance of Genomic Surveillance and Ongoing Research
The unpredictable nature of SARS-CoV-2 evolution highlights the necessity for continuous genomic surveillance and rapid response strategies. Monitoring mutations, especially in the spike protein, is crucial for early detection and management of new variants. Ongoing research and global collaboration are vital to adapt public health measures and guide vaccine updates as the virus continues to evolve Satapathy2024Scarpa2023Reinfeld2024+2 MORE.
Conclusion
BA.2.86 (Pirola) represents a significant development in the ongoing evolution of SARS-CoV-2, with a high number of mutations that may impact immune evasion and transmission. While it does not appear to be more severe than previous variants, its emergence reinforces the importance of surveillance, vaccination, and adaptable public health strategies to manage COVID-19 as it continues to change Satapathy2024Scarpa2023Abdolreza2024+4 MORE.
Sources and full results
Most relevant research papers on this topic
The emergence and implications of SARS-CoV-2 omicron subvariant BA.2.86 on global health
The SARS-CoV-2 subvariant BA.2.86 'Pirola' has the potential to amplify antibody responses, highlighting the need for ongoing research, adaptability, and global collaboration in early detection and management.
EG.5 (Eris) and BA.2.86 (Pirola) two new subvariants of SARS-CoV-2: a new face of old COVID-19
EG.5 and BA.2.86 subvariants of SARS-CoV-2 have similar features and are less immune evasive than ancestral SARS-CoV-2, potentially increasing the spread of the virus.
Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants
BA.2.86 and FLip SARS-CoV-2 variants show less immune evasion compared to FLip and other XBB variants, highlighting the need for updated COVID-19 vaccines.
The wind of change: Gibbs energy of binding and infectivity evolution of Omicron BA.2.86 Pirola, EG.5.1, XBB.1.16 Arcturus, CH.1.1 and BN.1 variants of SARS-CoV-2
The Omicron BA.2.86 Pirola SARS-CoV-2 variant has a lower binding force than BN.1, suggesting it may not be more aggressive than previous variants.
ADASYN: Oversampling Techniques for COVID-19 Prediction
The ADASYNA method effectively mitigates dataset imbalances and improves COVID-19 prediction accuracy compared to traditional oversampling techniques.
DOI